Mucopolysaccharidosis is a group of rare inherited disorders where the body cannot properly break down complex sugar molecules, leading to their harmful accumulation in cells throughout the body. While there is no cure, treatment approaches ranging from enzyme replacement therapy to innovative gene therapies are helping to manage symptoms and improve quality of life for those affected.

Understanding How Treatment Can Help Manage This Complex Condition

When a person receives a diagnosis of mucopolysaccharidosis (MPS), understanding the available treatment options becomes crucial for managing this progressive condition. The primary goal of treatment is not to cure the disease, but rather to slow its progression, reduce the severity of symptoms, and improve overall quality of life. Treatment decisions depend heavily on the specific type of MPS diagnosed, the stage of the disease, and individual patient characteristics such as age and the severity of symptoms present.^[1]

Medical societies have established standard treatment protocols for several types of MPS, particularly for the more common forms like MPS I and MPS II. These standard treatments have been carefully studied and approved for use in patients. At the same time, researchers continue to explore new therapeutic approaches through clinical trials, testing innovative drugs and treatment methods that may offer improved outcomes. Some patients may benefit from participating in these research studies, which investigate novel ways to address the underlying causes of MPS rather than just managing symptoms.^[3]

The treatment journey for MPS typically involves a team of medical specialists working together. This is because MPS affects multiple organ systems throughout the body, from the heart and lungs to the bones, joints, and in some cases, cognitive function. Coordinated care ensures that all aspects of the condition receive appropriate attention. Treatment plans are highly individualized and may need adjustment over time as the disease progresses or as new symptoms emerge.^[7]

Standard Treatment Approaches for Mucopolysaccharidosis

Enzyme replacement therapy (ERT) has become a cornerstone treatment for certain types of MPS. This approach works by providing the body with the missing or deficient enzyme that would normally break down glycosaminoglycans (GAGs). For MPS I, the medication laronidase (marketed as Aldurazyme) is used. This is a laboratory-produced version of the enzyme alpha-L-iduronidase. It is administered through an intravenous infusion, typically once weekly, and helps increase the breakdown of accumulated GAGs in the body.^[4]

Studies have shown that laronidase therapy can improve walking capacity and lung function in patients with MPS I. The medication is indicated for both Hurler syndrome (the severe form) and Hurler-Scheie syndrome (the intermediate form). However, it’s important to understand that enzyme replacement therapy has limitations. The enzymes administered intravenously cannot effectively cross the blood-brain barrier, which means they cannot address neurological symptoms related to brain involvement. This is a significant limitation for MPS types that primarily affect cognitive function.^[6][7]

For MPS II (Hunter syndrome), a different enzyme replacement therapy called idursulfase is available. This is a purified form of the enzyme iduronate-2-sulfatase, which breaks down the specific GAGs that accumulate in this type of MPS. Like laronidase, idursulfase is given as a weekly intravenous infusion. The medication works by replacing the insufficient enzyme levels, allowing cells to process and eliminate the accumulated sugar molecules more effectively.^[7]

Another enzyme replacement therapy, elosulfase alfa, has been approved specifically for MPS IV (Morquio A syndrome). This medication addresses the specific enzyme deficiency present in this form of the disease. Long-term studies suggest that continuous treatment with elosulfase alfa may be associated with partial recovery of physical abilities in patients with Morquio syndrome, though individual responses vary considerably.^[7]

For the rare MPS VII (Sly syndrome), vestronidase alfa (marketed as Mepsevii) received approval from the U.S. Food and Drug Administration. This enzyme replacement therapy has shown a reasonable tolerability profile, with most adverse reactions being mild to moderate in severity. However, as with other ERTs, it does not address symptoms affecting the central nervous system (brain and spinal cord).^[7][11]

Research examining the long-term effects of enzyme replacement therapy on cardiovascular complications has revealed mixed results. One study found that ERT significantly reduced left ventricular hypertrophy (thickening of the heart muscle) in both adult and pediatric patients with MPS. However, the therapy did not show significant beneficial effects on heart valve abnormalities, pulmonary hypertension (high blood pressure in the lungs), or enlargement of the left atrium of the heart. This underscores that while ERT helps with some aspects of the disease, it does not address all manifestations.^[7]

Hematopoietic stem cell transplantation (HSCT), also known as bone marrow transplantation, represents another established treatment approach, particularly for MPS I (Hurler syndrome). This procedure involves replacing a patient’s bone marrow with healthy stem cells from a donor. The transplanted cells produce the missing enzyme, theoretically providing a continuous source throughout the body. Children treated with HSCT generally have an increased lifespan compared to untreated children, who commonly died of cardiorespiratory complications in the first decade of life.^[7]

However, HSCT has significant limitations and risks. The procedure itself carries substantial risks including infection, graft rejection, and graft-versus-host disease (where the donor cells attack the recipient’s body). Moreover, the skeletal abnormalities characteristic of MPS—collectively called dysostosis multiplex—typically do not improve with bone marrow transplantation. X-rays of children treated with HSCT and those who are not treated usually look similar in terms of bone abnormalities. The timing of transplantation is critical; better outcomes are generally achieved when the procedure is performed early in the disease course, before irreversible damage occurs.^[7][8]

Beyond these disease-modifying treatments, supportive care plays an essential role in managing MPS. This includes addressing specific symptoms and complications as they arise. For example, approximately 70% of patients with MPS experience severe hearing loss, making routine audiological assessment and management extremely important for maintaining quality of life. Hearing aids or other assistive devices may be necessary.^[7]

Physical therapy and occupational therapy are important components of long-term management. Range-of-motion exercises performed at home help limit the progressive loss of joint mobility that commonly occurs in MPS patients. Night splinting—wearing supportive devices while sleeping—can help maintain joint position and function. Occupational aids and adaptive equipment assist patients in maintaining independence in daily activities despite physical limitations.^[7]

Surgical interventions are frequently required to address specific complications. Many MPS patients need procedures such as hernia repairs, insertion of ear tubes for chronic ear infections, heart valve replacement or repair, carpal tunnel release to relieve nerve compression in the wrists, and spinal surgery to address compression of the spinal cord. These surgeries carry higher risks in MPS patients due to underlying respiratory and cardiac disease, as well as anatomical abnormalities that can complicate anesthesia administration.^[7]

Innovative Therapies Being Tested in Clinical Trials

The limitations of current standard treatments have driven researchers to explore more advanced therapeutic approaches in clinical trials. One of the most promising areas of investigation is gene therapy, which aims to address the root cause of MPS by introducing functional copies of the defective gene into a patient’s cells. This approach could potentially provide a one-time treatment that enables the body to produce the missing enzyme continuously, eliminating the need for weekly infusions.^[6]

Gene therapy strategies for MPS are being tested in different phases of clinical trials. Phase I trials focus primarily on safety, determining whether the treatment is safe to give to humans and identifying appropriate dosing ranges. Phase II trials evaluate both safety and efficacy, examining whether the treatment actually improves disease parameters and symptoms in patients. Phase III trials compare the new treatment directly against current standard treatments to determine if it offers superior benefits.^[3]

One innovative gene therapy approach involves using a patient’s own blood cells as “factories” to produce the missing enzyme. In this technique, researchers collect blood cells from the patient, modify them in the laboratory to insert the correct gene, and then return these modified cells to the patient’s body. Once back in the body, these engineered cells continuously produce the enzyme, potentially providing long-term benefit from a single treatment. This approach is being investigated particularly for MPS I, with clinical trials ongoing to assess safety and effectiveness.^[6]

Another area of active research involves developing improved versions of enzyme replacement therapy that can better reach tissues that current ERTs cannot effectively treat. Scientists are working on modified enzymes that can cross the blood-brain barrier, which would allow treatment of the neurological symptoms that standard ERT cannot address. These modified enzymes are designed with special molecules attached that help them enter brain tissue. This is particularly important for types of MPS that cause significant cognitive decline, such as MPS III (Sanfilippo syndrome), for which no approved disease-modifying treatment currently exists.^[6]

Substrate reduction therapy represents another innovative approach being explored in clinical trials. Rather than replacing the missing enzyme or fixing the genetic defect, this strategy aims to reduce the production of glycosaminoglycans in the first place. By decreasing the amount of GAGs the body produces, there would be less accumulation in cells even without adequate enzyme function. Several molecules that work through this mechanism are in early-stage clinical testing for various forms of MPS.^[3][6]

Clinical trials for MPS treatments are being conducted in multiple countries including the United States, various European nations, and other regions. Patient eligibility for these trials varies depending on the specific study protocol. Generally, trials seek patients with confirmed diagnoses of specific MPS types, within certain age ranges, and meeting particular disease severity criteria. Some trials focus on patients who have not yet received other treatments, while others may enroll patients already on standard therapy to test whether adding a new treatment provides additional benefit.^[6]

Preliminary results from some clinical trials have shown encouraging signs. In certain gene therapy studies, patients have demonstrated improvements in clinical parameters such as reduced GAG levels in urine and blood, improved walking ability, and better pulmonary function. Some trials have also reported positive safety profiles, meaning that the treatments were generally well tolerated without causing serious adverse effects. However, it’s important to note that these are early results, and longer-term studies are needed to fully understand the benefits and risks of these novel approaches.^[6]

Advanced stem cell transplantation techniques are also being refined in clinical research settings. Scientists are working on methods to make the transplantation process safer and more effective, including using specially selected donor cells, implementing gentler conditioning regimens (the chemotherapy given before transplant), and developing strategies to prevent graft-versus-host disease. These improved transplantation protocols aim to preserve the benefits of HSCT while reducing its significant risks and complications.^[6]

Researchers are also investigating combination therapy approaches, where multiple treatments are used together. For example, some studies are examining whether combining enzyme replacement therapy with substrate reduction therapy might provide better outcomes than either treatment alone. The rationale is that attacking the problem from multiple angles—both increasing enzyme activity and reducing substrate production—might lead to more comprehensive disease control.^[6]

Most common treatment methods

• Enzyme Replacement Therapy
  • Laronidase (Aldurazyme) for MPS I – weekly intravenous infusions that provide the missing alpha-L-iduronidase enzyme
  • Idursulfase for MPS II – replaces the deficient iduronate-2-sulfatase enzyme through weekly infusions
  • Elosulfase alfa for MPS IV – addresses the specific enzyme deficiency in Morquio A syndrome
  • Vestronidase alfa (Mepsevii) for MPS VII – enzyme replacement approved for the rare Sly syndrome
  • Improves walking capacity, pulmonary function, and reduces GAG accumulation in many patients
  • Cannot effectively cross the blood-brain barrier, limiting treatment of neurological symptoms
• Hematopoietic Stem Cell Transplantation (Bone Marrow Transplantation)
  • Particularly used for severe MPS I (Hurler syndrome)
  • Replaces patient’s bone marrow with healthy donor stem cells that produce the missing enzyme
  • Can increase lifespan compared to untreated patients
  • Does not improve skeletal abnormalities (dysostosis multiplex)
  • Carries significant risks including infection, graft rejection, and graft-versus-host disease
  • Best outcomes achieved when performed early in disease course
• Supportive and Symptomatic Care
  • Hearing assessment and management for the approximately 70% of patients with hearing loss
  • Range-of-motion exercises and physical therapy to maintain joint mobility
  • Night splinting to preserve joint function
  • Occupational therapy and adaptive equipment for daily activities
  • Surgical interventions for complications such as hernias, carpal tunnel syndrome, heart valve problems, and spinal cord compression
• Gene Therapy (Investigational)
  • Aims to introduce functional copies of the defective gene into patient’s cells
  • Could potentially provide one-time treatment with long-lasting benefits
  • Uses patient’s own blood cells as “factories” to produce missing enzyme
  • Currently being tested in clinical trials for various MPS types
  • Early results show promise in reducing GAG levels and improving physical function
• Advanced Enzyme Replacement (Investigational)
  • Modified enzymes designed to cross the blood-brain barrier
  • Could address neurological symptoms that standard ERT cannot treat
  • Particularly important for MPS types with significant cognitive involvement like MPS III
  • Currently in various phases of clinical testing
• Substrate Reduction Therapy (Investigational)
  • Aims to reduce production of glycosaminoglycans rather than replacing the enzyme
  • Works by decreasing the amount of GAGs the body produces
  • Several molecules being tested in early-stage clinical trials
  • May be combined with enzyme replacement therapy for enhanced effect